Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time–kill study

摘要: Cystic fibrosis (CF) is a common and lethal genetic disorder with carrier frequency of 1 in 29 Caucasians. Chronic respiratory infections Pseudomonas aeruginosa are the leading cause morbidity mortality individuals CF. Aminoglycoside antibiotics, including gentamicin, highly effective against P. aeruginosa, but severe toxicity limits their use. One potential strategy for avoiding this problem to encapsulate aminoglycosides liposomes. In study, we compared bactericidal capacity liposome-encapsulated gentamicin that free antibiotic clinical isolates aeruginosa. Liposome size, encapsulation efficiency minimal inhibitory concentrations (MICs) liposomal gentamicin-sensitive -resistant strains were determined. vitro time–kill studies performed using at 1, 2 or 4 times MICs. The average size was 426.25 ± 13.56 nm, 4.51 0.54%. MICs significantly lower than those corresponding gentamicin. addition, values either equivalent better antibiotic. conclusion, our formulation more potent antipseudomonal drug an improved killing time prolonged antimicrobial activity.